Last reviewed · How we verify
AB-106
AB-106 is a TGF-β receptor inhibitor that blocks transforming growth factor-beta signaling to modulate immune responses and reduce fibrosis.
AB-106 is a TGF-β receptor inhibitor that blocks transforming growth factor-beta signaling to modulate immune responses and reduce fibrosis. Used for Advanced solid tumors (Phase 2 development).
At a glance
| Generic name | AB-106 |
|---|---|
| Also known as | DS-6051b |
| Sponsor | Nuvation Bio Inc. |
| Drug class | TGF-β receptor inhibitor |
| Target | TGF-β receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
AB-106 targets the TGF-β pathway, which plays a critical role in immune suppression and tissue fibrosis in various disease states. By inhibiting TGF-β receptor signaling, the drug aims to enhance anti-tumor immunity and reduce pathological fibrotic responses. This mechanism is being explored in oncology and potentially fibrotic disease indications.
Approved indications
- Advanced solid tumors (Phase 2 development)
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Anemia
Key clinical trials
- Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) (PHASE3)
- A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene (PHASE2)
- Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion (PHASE2)
- Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC (PHASE2)
- Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC
- Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression
- Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases
- Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AB-106 CI brief — competitive landscape report
- AB-106 updates RSS · CI watch RSS
- Nuvation Bio Inc. portfolio CI